Advanced
Order Entry
Austria
ContactUsLinkComponent
 
Human recombinant TNF alpha (from E. coli)
Catalog # PRSI92-216
Supplier:  ProSci Inc.
CAS Number:  
Human recombinant TNF alpha (from E. coli)
Catalog # PRSI92-216
Supplier:  ProSci Inc.
CAS Number:  

Specifications

  • Pk:
    50 µG
  • Protein/peptide type:
    Recombinant
  • Source:
    E. coli
  • Species:
    Human
  • Tag sequence:
    C-6 His tag
  • Storage conditions:
    Lyophilized protein should be stored at −20 °C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7 °C for 2-7 days. Aliquots of reconstituted samples are stable at −20 °C for 3 months.
  • Protein synonyms:
    TNF-a|TNFSF2|Tumor Necrosis Factor|TNF|TNFA|Cachectin|TNF-Alpha|Tumor Necrosis Factor Ligand Superfamily Member 2
  • Protein/peptide name:
    TNF alpha
  • Purity:
    > 95% as determined by reducing SDS-PAGE
  • Molecular weight:
    18.5 kD
  • Sequence:
    Val77-Leu233
  • Formulation:
    Lyophilized from a 0.2 um filtered solution of 20mM PB，150mM NaCl,pH7.4. Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 ug/ml. Dissolve the Lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
  • Tested applications:
    Bioassay

Specifications

About this item

tumour Necrosis Factor- alpha (TNF- alpha) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- alpha while cells that express CD8 secrete little or no TNF- alpha. Synthesis of TNF- alpha can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumour activity of TNF- alpha has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF- alpha mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- alpha that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumour activity and reduced systemic toxicity in mice compared with murine TNF- alpha, which binds to both murine TNF receptors. Based on these results, many TNF- alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumour cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- alpha High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.

Fusion-Tag: C-6 His tag

This recombinant protein can be used for biological assays. For research use only.